Ricardo Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricardo Neto has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Mariana Diz-Lopes
Rheumatology Department, Unidade Local de Saúde de São João, Porto, Portugal
6 shared publications - Bernardo José Cardoso Fernandes
Universidade do Porto, Portugal; Unidade Local de Saúde de São João, Portugal
5 shared publications João Frazão
RISE-Health, Faculty of Medicine, University of Porto , Porto
5 shared publicationsJuliana Magalhães
Department of Medicine, Faculty of Medicine, University of Porto , Porto
4 shared publications- Teresa Martins-Rocha
Unidade Local de Saúde de São João, Portugal; Universidade do Porto, Portugal
4 shared publications - Janete Quelhas-Santos
RISE-Health, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (10) , sfag346
Albuminuria is associated with higher turnover-related bone histomorphometric indices in chronic kidney disease stages 3–4
Background: Biological determinants of bone turnover in chronic kidney disease (CKD) remain incompletely understood. Although albuminuria is an established marker of kidney damage and predictor of renal and cardiovascular outcomes, its relationship with bone remodeling, as assessed by quantitative bone histomorphometry, has not previously been investigated. Methods: We performed a cross-sectional study of 56 adults with CKD stages 3–4 who underwent transiliac bone biopsy with quantitative histomorphometry following double tetracycline labeling. Associations between 24-h urinary albumin excretion and individual bone histomorphometric parameters were evaluated using multivariable linear regression. Models were adjusted for age, sex, estimated glomerular filtration rate (eGFR), intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF23). Results: In multivariable analyses, higher 24-h urinary albumin excretion was associated with a histomorphometric pattern consistent with increased bone turnover, reflected by greater bone formation and cell surface indices. Specifically, log₁₀-transformed urinary albumin excretion was associated with higher bone formation rate (B = 0.295, 95% CI 0.088 to 0.501; P = 0.008), osteoblast surface (B = 0.588, 95% CI 0.187 to 0.988; P = 0.005) and osteoclast surface (B = 0.464, 95% CI 0.041 to 0.887; P = 0.033). Associations with mineralization-related parameters and bone volume were not statistically significant. Conclusions: In patients with CKD stages 3–4, higher urinary albumin excretion was independently associated with quantitative histomorphometric indices of higher bone turnover. These findings suggest that albuminuria may mark a bone remodeling phenotype not fully captured by eGFR, iPTH, and FGF23. Larger prospective studies are needed to define the biological basis and clinical implications of this association.
- 1 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (10) , sfag346
Open AccessAlbuminuria is associated with higher turnover-related bone histomorphometric indices in chronic kidney disease stages 3–4
Background: Biological determinants of bone turnover in chronic kidney disease (CKD) remain incompletely understood. Although albuminuria is an established marker of kidney damage and predictor of renal and cardiovascular outcomes, its relationship with bone remodeling, as assessed by quantitative bone histomorphometry, has not previously been investigated. Methods: We performed a cross-sectional study of 56 adults with CKD stages 3–4 who underwent transiliac bone biopsy with quantitative histomorphometry following double tetracycline labeling. Associations between 24-h urinary albumin excretion and individual bone histomorphometric parameters were evaluated using multivariable linear regression. Models were adjusted for age, sex, estimated glomerular filtration rate (eGFR), intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF23). Results: In multivariable analyses, higher 24-h urinary albumin excretion was associated with a histomorphometric pattern consistent with increased bone turnover, reflected by greater bone formation and cell surface indices. Specifically, log₁₀-transformed urinary albumin excretion was associated with higher bone formation rate (B = 0.295, 95% CI 0.088 to 0.501; P = 0.008), osteoblast surface (B = 0.588, 95% CI 0.187 to 0.988; P = 0.005) and osteoclast surface (B = 0.464, 95% CI 0.041 to 0.887; P = 0.033). Associations with mineralization-related parameters and bone volume were not statistically significant. Conclusions: In patients with CKD stages 3–4, higher urinary albumin excretion was independently associated with quantitative histomorphometric indices of higher bone turnover. These findings suggest that albuminuria may mark a bone remodeling phenotype not fully captured by eGFR, iPTH, and FGF23. Larger prospective studies are needed to define the biological basis and clinical implications of this association.
- 27 August 2026
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 21 (1) , 131
Fragility fractures and risk factors in a peritoneal dialysis setting
Summary Peritoneal dialysis patients have poorly characterized fracture risk. In this retrospective cohort of 325 patients, fragility fractures were frequent, mainly asymptomatic vertebral fractures. Fracture risk is independently associated with prior fractures and vascular calcification but FRAX® underestimates fracture risk, underscoring the need for improved assessment strategies tailored to peritoneal dialysis patients. Purpose Data on fracture incidence, risk factors, and fracture risk assessment tools in patients treated with peritoneal dialysis (PD) remain limited. We aimed to evaluate the prevalence, incidence, and determinants of fragility fractures in PD patients and to assess the performance of the Fracture Risk Assessment Tool (FRAX®). Methods Retrospective single-center cohort study including adult patients receiving PD for ≥ 12 months. Fragility fractures occurring during PD follow-up were identified through clinical records and review of spine radiographs. Vascular calcification was assessed using the Adragão vascular calcification score (VCS). FRAX® probabilities for fracture risk were calculated without bone mineral density. Logistic regression was used to identify independent predictors of fractures, and receiver operating characteristic (ROC) curves evaluated FRAX® performance. Results Among 325 patients receiving PD (mean age 53 ± 8 years, 57% male), 32 (9.8%) fragility fractures were identified, and most were asymptomatic vertebral fractures (n = 23, 7.1%). In multivariable analysis, previous fracture history (OR 4.85, 95% CI 1.22–19.27) and higher VCS (OR 2.10, 95% CI 1.10–4.03) were independently associated with fracture occurrence. FRAX® showed modest discriminatory ability for any fragility fracture (AUC 0.69) and very low sensitivity at standard intervention thresholds, even when CKD was classified as secondary osteoporosis. Conclusion Patients treated with PD experience a high burden of fragility fractures, largely driven by unrecognized vertebral fractures. Fracture risk is independently associated with prior fractures and vascular calcification. FRAX® underestimates fracture risk in this population, underscoring the need for improved fracture risk assessment strategies tailored to PD patients.
- 27 August 2026
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 21 (1) , 131
Fragility fractures and risk factors in a peritoneal dialysis setting
Summary Peritoneal dialysis patients have poorly characterized fracture risk. In this retrospective cohort of 325 patients, fragility fractures were frequent, mainly asymptomatic vertebral fractures. Fracture risk is independently associated with prior fractures and vascular calcification but FRAX® underestimates fracture risk, underscoring the need for improved assessment strategies tailored to peritoneal dialysis patients. Purpose Data on fracture incidence, risk factors, and fracture risk assessment tools in patients treated with peritoneal dialysis (PD) remain limited. We aimed to evaluate the prevalence, incidence, and determinants of fragility fractures in PD patients and to assess the performance of the Fracture Risk Assessment Tool (FRAX®). Methods Retrospective single-center cohort study including adult patients receiving PD for ≥ 12 months. Fragility fractures occurring during PD follow-up were identified through clinical records and review of spine radiographs. Vascular calcification was assessed using the Adragão vascular calcification score (VCS). FRAX® probabilities for fracture risk were calculated without bone mineral density. Logistic regression was used to identify independent predictors of fractures, and receiver operating characteristic (ROC) curves evaluated FRAX® performance. Results Among 325 patients receiving PD (mean age 53 ± 8 years, 57% male), 32 (9.8%) fragility fractures were identified, and most were asymptomatic vertebral fractures (n = 23, 7.1%). In multivariable analysis, previous fracture history (OR 4.85, 95% CI 1.22–19.27) and higher VCS (OR 2.10, 95% CI 1.10–4.03) were independently associated with fracture occurrence. FRAX® showed modest discriminatory ability for any fragility fracture (AUC 0.69) and very low sensitivity at standard intervention thresholds, even when CKD was classified as secondary osteoporosis. Conclusion Patients treated with PD experience a high burden of fragility fractures, largely driven by unrecognized vertebral fractures. Fracture risk is independently associated with prior fractures and vascular calcification. FRAX® underestimates fracture risk in this population, underscoring the need for improved fracture risk assessment strategies tailored to PD patients.
- 12 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 39 (7) , 1522-1523
A close look at the bone in secondary hyperparathyroidism corrected with calcifediol
- 12 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 39 (7) , 1522-1523
A close look at the bone in secondary hyperparathyroidism corrected with calcifediol
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3)
Resposta à carta: os métodos não invasivos substituirão a biópsia óssea nos pacientes com doença renal crônica?
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3)
Open AccessResposta à carta: os métodos não invasivos substituirão a biópsia óssea nos pacientes com doença renal crônica?
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3)
Reply to the letter: will non-invasive methods replace bone biopsy in patients with chronic kidney disease?
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (3)
Open AccessReply to the letter: will non-invasive methods replace bone biopsy in patients with chronic kidney disease?
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Impacto da histomorfometria óssea, biomarcadores ósseos e FRAX® em fraturas em pacientes com DRC em pré-diálise
Resumo Introdução: Pacientes com doença renal crônica (DRC) apresentam risco aumentado de fraturas. Atualmente, não está estabelecido se o tipo de osteodistrofia renal (ODR) contribui para esse risco, pois biópsias ósseas não são frequentemente realizadas na prática clínica. Nosso objetivo foi avaliar a associação entre subtipos de ODR, biomarcadores ósseos e risco de fraturas determinado pela ferramenta FRAX® com a ocorrência de fraturas em pacientes com DRC pré-diálise. Métodos: Estudo retrospectivo com pacientes acompanhados entre 2014–2023. Realizaram-se exames de sangue – incluindo biomarcadores ósseos (BRB) – e biópsias ósseas no início do acompanhamento. Dados de densitometria óssea (DXA) e fraturas clinicamente evidentes foram obtidos de registros médicos. Avaliaram-se radiografias da coluna torácica/lombar para detectar fraturas vertebrais. O índice FRAX®, sem densidade mineral óssea (DMO), foi calculado com ferramenta online. Resultados: O tempo médio de acompanhamento foi 7,5 ± 3 anos; 9,3% dos pacientes apresentaram fratura óssea, com incidência de 12/1000 pacientes-ano. Pacientes que sofreram fratura exibiram níveis mais elevados de fósforo (4,1 mg/dL vs. 3,5 mg/dL; p = 0,047). Os subtipos histomorfométricos e os BRB não foram associados à incidência de fraturas nem ao risco de fraturas avaliado pelo FRAX®. Houve tendência a menor volume ósseo no grupo com fraturas (p = 0,057). FRAX® (sem DMO), independentemente da inclusão da DRC como osteoporose secundária, apresentou boa precisão diagnóstica global para prever fraturas na DRC pré-diálise. Conclusão: Os subtipos de ODR não foram associados à incidência de fraturas nesses pacientes. A capacidade discriminatória do FRAX nessa população enfatiza sua utilidade em pacientes com DRC pré-diálise.
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Open AccessImpacto da histomorfometria óssea, biomarcadores ósseos e FRAX® em fraturas em pacientes com DRC em pré-diálise
Resumo Introdução: Pacientes com doença renal crônica (DRC) apresentam risco aumentado de fraturas. Atualmente, não está estabelecido se o tipo de osteodistrofia renal (ODR) contribui para esse risco, pois biópsias ósseas não são frequentemente realizadas na prática clínica. Nosso objetivo foi avaliar a associação entre subtipos de ODR, biomarcadores ósseos e risco de fraturas determinado pela ferramenta FRAX® com a ocorrência de fraturas em pacientes com DRC pré-diálise. Métodos: Estudo retrospectivo com pacientes acompanhados entre 2014–2023. Realizaram-se exames de sangue – incluindo biomarcadores ósseos (BRB) – e biópsias ósseas no início do acompanhamento. Dados de densitometria óssea (DXA) e fraturas clinicamente evidentes foram obtidos de registros médicos. Avaliaram-se radiografias da coluna torácica/lombar para detectar fraturas vertebrais. O índice FRAX®, sem densidade mineral óssea (DMO), foi calculado com ferramenta online. Resultados: O tempo médio de acompanhamento foi 7,5 ± 3 anos; 9,3% dos pacientes apresentaram fratura óssea, com incidência de 12/1000 pacientes-ano. Pacientes que sofreram fratura exibiram níveis mais elevados de fósforo (4,1 mg/dL vs. 3,5 mg/dL; p = 0,047). Os subtipos histomorfométricos e os BRB não foram associados à incidência de fraturas nem ao risco de fraturas avaliado pelo FRAX®. Houve tendência a menor volume ósseo no grupo com fraturas (p = 0,057). FRAX® (sem DMO), independentemente da inclusão da DRC como osteoporose secundária, apresentou boa precisão diagnóstica global para prever fraturas na DRC pré-diálise. Conclusão: Os subtipos de ODR não foram associados à incidência de fraturas nesses pacientes. A capacidade discriminatória do FRAX nessa população enfatiza sua utilidade em pacientes com DRC pré-diálise.
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20240276
The impact of bone histomorphometry, bone-related biomarkers, and FRAX® on fractures patients with predialysis CKD
Introduction: Chronic kidney disease (CKD) patients are at increased risk of fracture. Whether the type of renal osteodystrophy (ROD) contributes to fracture risk is not currently established since bone biopsies are not frequently performed in clinical practice. We aimed to evaluate the association of ROD subtypes, bone biomarkers, and fracture risk assessed with the FRAX® tool with the occurrence of fractures in predialysis CKD patients. Methods: Retrospective study with patients followed between 2014–2023. Blood tests, including bone-related biomarkers (BRB), and bone biopsies were performed at the beginning of follow-up. Data from dual x-ray absorptiometry (DXA) scan and clinically evident fractures were obtained from medical registries. Radiographs of the thoracic/lumbar spine were evaluated to detect vertebral fractures, and the FRAX® index without bone mineral density (BMD) was calculated with the web-based tool. Results: Median follow-up time was 7.5 ± 3 years and 9.3% of the patients had a bone fracture, with an incidence of 12/1000 patient-year. Patients who had a fracture had higher phosphorus levels (4.1 mg/dL vs 3.5 mg/dL, p = 0.047). Histomorphometric subtypes and BRB were not associated with incidence of fractures nor with fracture risk assessed by FRAX®. There was a tendency for lower bone volume in the group with fractures (p = 0.057). FRAX® (without BMD), regardless of the inclusion of CKD as secondary osteoporosis, showed an overall good diagnostic accuracy for predicting fractures in predialysis CKD. Conclusion: ROD subtypes were not associated with incidence of fractures in these patients. The discriminative ability of FRAX in this population emphasizes its usefulness in CKD predialysis patients.
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20240276
Open AccessThe impact of bone histomorphometry, bone-related biomarkers, and FRAX® on fractures patients with predialysis CKD
Introduction: Chronic kidney disease (CKD) patients are at increased risk of fracture. Whether the type of renal osteodystrophy (ROD) contributes to fracture risk is not currently established since bone biopsies are not frequently performed in clinical practice. We aimed to evaluate the association of ROD subtypes, bone biomarkers, and fracture risk assessed with the FRAX® tool with the occurrence of fractures in predialysis CKD patients. Methods: Retrospective study with patients followed between 2014–2023. Blood tests, including bone-related biomarkers (BRB), and bone biopsies were performed at the beginning of follow-up. Data from dual x-ray absorptiometry (DXA) scan and clinically evident fractures were obtained from medical registries. Radiographs of the thoracic/lumbar spine were evaluated to detect vertebral fractures, and the FRAX® index without bone mineral density (BMD) was calculated with the web-based tool. Results: Median follow-up time was 7.5 ± 3 years and 9.3% of the patients had a bone fracture, with an incidence of 12/1000 patient-year. Patients who had a fracture had higher phosphorus levels (4.1 mg/dL vs 3.5 mg/dL, p = 0.047). Histomorphometric subtypes and BRB were not associated with incidence of fractures nor with fracture risk assessed by FRAX®. There was a tendency for lower bone volume in the group with fractures (p = 0.057). FRAX® (without BMD), regardless of the inclusion of CKD as secondary osteoporosis, showed an overall good diagnostic accuracy for predicting fractures in predialysis CKD. Conclusion: ROD subtypes were not associated with incidence of fractures in these patients. The discriminative ability of FRAX in this population emphasizes its usefulness in CKD predialysis patients.
- 1 July 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 98 (1) , 17-25
Effect of vitamin D sterols on bone histology in pre-dialysis patients: A prospective controlled study
Background: Abnormalities related to mineral and bone metabolism are a common finding in chronic kidney disease (CKD). Vitamin D compounds are often prescribed to CKD patients with the purpose to control secondary hyperparathyroidism and reduce the risk of high-turnover bone disease. However, data on the effect of vitamin D sterols on bone histology in non-dialysis CKD is limited. Materials and methods: A prospective controlled study was conducted on a cohort of 56 patients with CKD stages 3 and 4. 19 patients on calcitriol and 12 patients on cholecalciferol were compared to a group of 25 age-and sex-matched controls. Participants underwent a tetracycline double-labelled transiliac bone biopsy before starting therapy and again 12 months later. Changes from baseline in circulating biomarkers and bone histomorphometric parameters were analyzed. Results: Low turnover bone disease was the most common pattern of renal osteodystrophy on the initial biopsy. There was no difference in biochemical or histomorphometric values between the three study groups at baseline. Serum intact parathormone (iPTH) and bone formation rate decreased significantly in calcitriol-treated patients, with prevalence of low-turnover bone disease doubling from baseline. In contrast, no significant changes were noted in cholecalciferol-treated and control subjects. Conclusion: Calcitriol was effective in preventing secondary hyperparathyroidism and high-turnover bone disease. However, it was associated with an increased risk of developing or aggravating low-turnover bone disease. In the absence of a bone biopsy, calcitriol use in pre-dialysis CKD should be reserved for patients with a progressive rise in iPTH levels, in whom high-turnover bone disease is suspected.
- 1 July 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 98 (1) , 17-25
Effect of vitamin D sterols on bone histology in pre-dialysis patients: A prospective controlled study
Background: Abnormalities related to mineral and bone metabolism are a common finding in chronic kidney disease (CKD). Vitamin D compounds are often prescribed to CKD patients with the purpose to control secondary hyperparathyroidism and reduce the risk of high-turnover bone disease. However, data on the effect of vitamin D sterols on bone histology in non-dialysis CKD is limited. Materials and methods: A prospective controlled study was conducted on a cohort of 56 patients with CKD stages 3 and 4. 19 patients on calcitriol and 12 patients on cholecalciferol were compared to a group of 25 age-and sex-matched controls. Participants underwent a tetracycline double-labelled transiliac bone biopsy before starting therapy and again 12 months later. Changes from baseline in circulating biomarkers and bone histomorphometric parameters were analyzed. Results: Low turnover bone disease was the most common pattern of renal osteodystrophy on the initial biopsy. There was no difference in biochemical or histomorphometric values between the three study groups at baseline. Serum intact parathormone (iPTH) and bone formation rate decreased significantly in calcitriol-treated patients, with prevalence of low-turnover bone disease doubling from baseline. In contrast, no significant changes were noted in cholecalciferol-treated and control subjects. Conclusion: Calcitriol was effective in preventing secondary hyperparathyroidism and high-turnover bone disease. However, it was associated with an increased risk of developing or aggravating low-turnover bone disease. In the absence of a bone biopsy, calcitriol use in pre-dialysis CKD should be reserved for patients with a progressive rise in iPTH levels, in whom high-turnover bone disease is suspected.
- Open Access
- 17 January 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (2) , 457
Could Bone Biomarkers Predict Bone Turnover after Kidney Transplantation?—A Proof-of-Concept Study
Aim: Bone disease after kidney transplant (KT) results from multiple factors, including previous bone and mineral metabolism disturbances and effects of transplant-related medications. New biomolecules have been recently associated with the development and progression of the chronic kidney disease–associated bone and mineral disorder (CKD-MBD). These include sclerostin and the soluble receptor activator of nuclear factor-kB ligand (sRANKL). Methods: To better understand the role of biomarkers in post-transplant bone disease, this study was designed to prospectively evaluate and correlate results from the histomorphometric analysis of bone biopsies after KT with emerging serum biomarkers of the CKD-MBD: sclerostin, Dickkopf-related protein 1 (Dkk-1), sRANKL and osteo-protegerin (OPG). Results: Our data shows a significant increase in plasma levels of bioactive sclerostin after KT accompanied by a significant reduction in plasma levels of Dkk-1, suggesting a promotion of the inhibition of bone formation by osteoblasts through the activation of these inhibitors of the Wnt signaling pathway. In addition, we found a significant increase in plasma levels of free sRANKL after KT accompanied by a significant reduction in plasma levels of its decoy receptor OPG, suggesting an enhanced bone resorption by osteoclasts mediated by this mechanism. Conclusions: Taken together, these results suggest that the loss of bone volume observed after KT could be explain mainly by the inhibition of bone formation mediated by sclerostin accompanied by an enhanced bone resorption mediated by sRANKL.
- 17 January 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (2) , 457
Open AccessCould Bone Biomarkers Predict Bone Turnover after Kidney Transplantation?—A Proof-of-Concept Study
Aim: Bone disease after kidney transplant (KT) results from multiple factors, including previous bone and mineral metabolism disturbances and effects of transplant-related medications. New biomolecules have been recently associated with the development and progression of the chronic kidney disease–associated bone and mineral disorder (CKD-MBD). These include sclerostin and the soluble receptor activator of nuclear factor-kB ligand (sRANKL). Methods: To better understand the role of biomarkers in post-transplant bone disease, this study was designed to prospectively evaluate and correlate results from the histomorphometric analysis of bone biopsies after KT with emerging serum biomarkers of the CKD-MBD: sclerostin, Dickkopf-related protein 1 (Dkk-1), sRANKL and osteo-protegerin (OPG). Results: Our data shows a significant increase in plasma levels of bioactive sclerostin after KT accompanied by a significant reduction in plasma levels of Dkk-1, suggesting a promotion of the inhibition of bone formation by osteoblasts through the activation of these inhibitors of the Wnt signaling pathway. In addition, we found a significant increase in plasma levels of free sRANKL after KT accompanied by a significant reduction in plasma levels of its decoy receptor OPG, suggesting an enhanced bone resorption by osteoclasts mediated by this mechanism. Conclusions: Taken together, these results suggest that the loss of bone volume observed after KT could be explain mainly by the inhibition of bone formation mediated by sclerostin accompanied by an enhanced bone resorption mediated by sRANKL.
- Open Access
- 13 October 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (10) , e0258284
Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients
Background: Vascular calcification (VC) is a common finding in chronic kidney disease (CKD) patients and predicts subsequent cardiovascular morbidity and mortality in this population. Vascular calcification is linked to disordered mineral metabolism and has been associated with bone histomorphometry changes in CKD. However, data on predialysis patients is scarce. Methods: A cross-sectional study was conducted on a cohort of 56 CKD patients not yet on dialysis, who underwent a transiliac bone biopsy for histomorphometric evaluation after double tetracycline labeling. Patients had no previous exposure to calcium salts, vitamin D agents, steroids or bisphosphonates. Vascular calcification was assessed at the time of biopsy, using Kauppila (plain X-ray of the lateral lumbar spine) and Adragão (plain X-ray of the pelvis and hands) scores. Results: Vascular calcification was seen in two-thirds of the cohort. Subjects with VC were more likely to be male and have diabetes, and had significantly higher sclerostin and osteoprotegerin circulating levels than those without VC. The histomorphometric analysis showed that bone formation rate was significantly lower in VC compared to non-VC patients. In the multivariable logistic regression analysis, bone formation rate was independently associated with the presence of VC. Conclusions: Vascular calcification is highly prevalent in predialysis patients, especially in those with diabetes. The independent association between bone formation rate and VC provides evidence of an important interaction between bone and vessel in CKD. Our results suggest that low bone turnover is a non-traditional risk factor for cardiovascular disease in predialysis patients.
- 13 October 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (10) , e0258284
Open AccessLow bone turnover is associated with plain X-ray vascular calcification in predialysis patients
Background: Vascular calcification (VC) is a common finding in chronic kidney disease (CKD) patients and predicts subsequent cardiovascular morbidity and mortality in this population. Vascular calcification is linked to disordered mineral metabolism and has been associated with bone histomorphometry changes in CKD. However, data on predialysis patients is scarce. Methods: A cross-sectional study was conducted on a cohort of 56 CKD patients not yet on dialysis, who underwent a transiliac bone biopsy for histomorphometric evaluation after double tetracycline labeling. Patients had no previous exposure to calcium salts, vitamin D agents, steroids or bisphosphonates. Vascular calcification was assessed at the time of biopsy, using Kauppila (plain X-ray of the lateral lumbar spine) and Adragão (plain X-ray of the pelvis and hands) scores. Results: Vascular calcification was seen in two-thirds of the cohort. Subjects with VC were more likely to be male and have diabetes, and had significantly higher sclerostin and osteoprotegerin circulating levels than those without VC. The histomorphometric analysis showed that bone formation rate was significantly lower in VC compared to non-VC patients. In the multivariable logistic regression analysis, bone formation rate was independently associated with the presence of VC. Conclusions: Vascular calcification is highly prevalent in predialysis patients, especially in those with diabetes. The independent association between bone formation rate and VC provides evidence of an important interaction between bone and vessel in CKD. Our results suggest that low bone turnover is a non-traditional risk factor for cardiovascular disease in predialysis patients.